

Response
<p><b>2</b></p> <p>The Department may, at its discretion, publish part or all of the information provided in your submission on the Department's website or in related documents. If information from your submission is published, the Department may identify you and/or your organisation as the author of the submission. All personal contact details will be removed prior to publishing.</p> <p>Yes, I consent to my identified submission being published</p>
<p><b>3</b></p> <p>What is your name?</p> <p>Belinda Wood</p>
<p><b>7</b></p> <p>Please select the type of individual(s) or organisation(s) you represent. Please select all that apply. - Selected Choice</p> <p>Pharmaceutical / Medical technology company</p>
<p><b>8.1</b></p> <p>What is the name of your organisation? - My organisation is called: - Text</p> <p>Gilead Sciences</p>
<p><b>9</b></p> <p>Are you making feedback on behalf of your organisation?</p> <p>Your organisation</p>
<p><b>13</b></p> <p>Please select which chapter/s you would like to provide feedback on. You may provide feedback on as many or few chapters as you wish.</p> <p>4. Health technology funding and purchasing approaches and managing uncertainty</p>
<p><b>17</b></p> <p>Please select the topics within the chapter(s) you would like to provide feedback on. 4. Health Technology funding and purchasing mechanisms and decisions</p> <p>4.1. Approaches to funding or purchasing new health technologies</p>
<p><b>103</b></p> <p>Taking all Options within this section: 4.1. Approaches to funding or purchasing new health technologies into account.</p> <p>Overall, to what extent could the options (if implemented) address the issues that relate to them?</p> <p>Address little or none of the issue(s)</p>
<p><b>104</b></p> <p>If you would like to expand on your answer above you can do so below:</p> <p>Please see attached PDF submission</p>
<p><b>105.1</b></p> <p>If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Recognising competition between new health technologies that deliver similar outcomes:</p> <p>Alternative option 1: In conjunction with options for proportionate assessment of cost-minimisation submissions, require offers of a lower price for health technologies that provide no added benefit</p> <p>Very negative</p>
<p><b>105.2</b></p> <p>If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Recognising competition between new health technologies that deliver similar outcomes:</p> <p>Alternative option 2: In conjunction with options for proportionate assessment of cost-minimisation submissions, incentivise offers of a lower price for health technologies that provide no added benefit</p> <p>Very negative</p>
<p><b>105.3</b></p> <p>If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Investigate further options to address budget impact implications of high-cost/high impact health technologies</p> <p>Very negative</p>
<p><b>105.4</b></p> <p>If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Pricing offer (PO) and negotiation guidance framework</p> <p>Very negative</p>
<p><b>105.5</b></p> <p>If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Post-listing re-assessment of health technologies</p> <p>Very negative</p>
<p><b>105.6</b></p> <p>If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Approaches for managing uncertainty - bridging funding coverage for earlier access to therapies of likely HATV and HUCN</p> <p>Very negative</p>
<p><b>105.7</b></p> <p>If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Approaches for managing uncertainty - revised guidance on the uses of different managed entry tools</p> <p>Very negative</p>
<p><b>167</b></p> <p>In summary, considering all the draft reform options together:</p> <p>How confident are you that the reform options (if implemented) will make health technology assessments better overall?</p> <p>Not at all confident</p>
<p><b>238.1</b></p> <p>Under the subject 'Recognising competition between new health technologies that deliver similar outcomes', there are two options that provide different alternative mechanisms to address the issues that relate to them.</p> <p>To what extent could the below different alternative options (if implemented) address the issues that relate to them? - Alternative option 1: In conjunction with options for proportionate assessment of cost-minimisation submissions, require offers of a lower price for health technologies that provide no added benefit</p> <p>Not at all</p>
<p><b>238.2</b></p> <p>Under the subject 'Recognising competition between new health technologies that deliver similar outcomes', there are two options that provide different alternative mechanisms to address the issues that relate to them.</p> <p>To what extent could the below different alternative options (if implemented) address the issues that relate to them? - Alternative option 2: In conjunction with options for proportionate assessment of cost-minimisation submissions, incentivise offers of a lower price for health technologies that provide no added benefit.</p> <p>Not at all</p>
<p><b>240</b></p> <p>Which of the proposed reform options do you think offers greatest scope to address the issues identified in consultation to date?</p> <p>Neither of these</p>